Exploratory Only Signal

KRAS G12C

pancreatic cancer · Combination Therapy

KRAS G12C is flagged as exploratory only signal because public trials show mention only evidence in 1 contexts. FDA CDx context should be reviewed manually.

Back to report

Role evidence

Usage summary

Strongest role: Mention Only

Inclusion-required count: 0

Treatment-assignment count: 0

Stratification count: 0

Threshold snippets

Fragmentation view

Threshold count: 0

Common snippets: None extracted

Threshold label: Low

FDA CDx context

Mapping summary

CDx label: Fda Cdx Context Not Found

CDx maturity score: 1/5

Confidence: Medium

Patent-density signal

Diagnostic appendix

Signal count: 1

Recent signals: 1

Density label: Low

Source links

Evidence paths

https://clinicaltrials.gov/study/NCT01693419